# TAO Synergies Inc.: Form 10-Q for the period ended Jun 30, 2023

- Company: [TAO Synergies Inc.](/companies/taox.md) (CIK 1571934)
- Form: 10-Q
- Filed: 2023-08-14
- Accepted by EDGAR: Aug 14, 2023, 17:00 ET
- Period: 2023-06-30
- Accession: 0001410578-23-001919
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1571934/000141057823001919/snpx-20230630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1571934/000141057823001919/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2023-04-01 to 2023-06-30 | $307.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2023-01-01 to 2023-06-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$4.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | −$5.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | $1.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | $1.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | $1.39 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | $1.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 7,361,300 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 7,356,600 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$2.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $2.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-06-30 | $32.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $33.4m | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $33.4m | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $6.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $24.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,226 characters.

*You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our annual report on Form 10-K for the year ended December 31, 2022.*

*The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on the unaudited financial statements contained in this report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.*

### Basis of Presentation

The unaudited financial statements for the six months ended June 30, 2023 and 2022 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in the financial statements. All such adjustments are of a normal recurring nature.

### Overview

We are a biopharmaceutical company with product candidates in pre-clinical and clinical development. We began operations in October 2012. We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease, which is in the clinical testing stage. We are also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Neurotrope, our predecessor company, had been a party to a technology license and services agreement with the original Blanchette Rockefeller Neurosciences Institute (which has been known as Cognitive Research Enterprises, Inc. since October 2016), and its affiliate NRV II, LLC, which we collectively refer to herein as “CRE,” pursuant to which we now have an exclusive non-transferable license to certain patents and technologies required to develop our proposed products. We were formed for the primary purpose of commercializing the technologies initially developed by BRNI for therapeutic applications for AD or other cognitive dysfunctions. These technologies have been under development by BRNI since 1999 and, until March 2013, had been financed through funding from a variety of non-investor sources (which include not-for-profit foundations, the NIH, which is part of the U.S. Department of Health and Human Services, and individual philanthropists). From March 2013 forward, development of the licensed technology has been funded principally through us in collaboration with CRE.

### November 2022 Private Placement

On November 17, 2022, we entered into the November Purchase Agreement with the November Investors, pursuant to which we agreed to sell to the November Investors (i) an aggregate of 15,000 shares of Series B Preferred Stock and (ii) November Warrants to acquire up to an aggregate of 1,935,485 shares of Common Stock. We received total gross proceeds of approximately $15 million from the November Private Placement.

The terms of the Series B Preferred Stock are as set forth in the Certificate of Designations. The Series B Preferred Stock will be convertible into Series B Preferred Shares at the election of the holder at any time at the Conversion Price. The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). We will be required to redeem the Series B Preferred Stock in 15 equal monthly installments, commencing on June 1, 2023. The amortization payments due upon such redemption are payable, at our election, in cash, or subject to certain limitations, in shares of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 15% discount to the average of the three lowest closing prices of the Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $1.25 and $0.172, which is equal to 20% of the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) on April 14, 2023, the date of receipt of Nasdaq Stockholder Approval (as defined below); provided that if the amount set forth in clause B is the lowest effective price, we will be required to pay the amortization payment in cash. We may require holders to convert their Series B Preferred Stock into Series B Preferred Shares if the closing price of the Common Stock exceeds $11.625 per share for 20 consecutive trading days and the daily trading volume of the Common Stock exceeds 100,000 shares per day during the same period and certain equity conditions described in the Certificate of Designations are satisfied.

The holders of the Series B Preferred Stock are entitled to dividends of 7% per annum, compounded monthly, which are payable in cash or shares of Common Stock at our option, in accordance with the terms of the Certificate of Designations. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series B Preferred Stock will accrue dividends at the rate of 15% per annum. The holders of Series B Preferred Stock have no voting rights on account of the Series B Preferred Stock, other than with respect to certain matters affecting the rights of the Series B Preferred Stock.

Notwithstanding the foregoing, our ability to settle conversions and make amortization payments using shares of Common Stock is subject to certain limitations set forth in the Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that our stockholders have approved the issuance of more than 19.9% of our outstanding shares of Common Stock in accordance with Nasdaq listing standards (the “Nasdaq Stockholder Approval”). We agreed to seek stockholder approval of these matters at a meeting to be held no later than June 1, 2023, and such approval was obtained at the Company’s special meeting of stockholders held on April 14, 2023. Further, the Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of Common Stock issuable upon conversion of, or as part of any amortization payment under, the Certificate of Designations or November Warrants.

The Certificate of Designations includes certain Triggering Events (as defined in the Certificate of Designations), including, among other things, the failure to file and maintain an effective registration statement covering the sale of the holder’s securities registrable pursuant to the November Registration Rights Agreement (defined below) and our failure to pay any amounts due to the holders of the Series B Preferred Stock when due. In connection with a Triggering Event, each holder of Series B Preferred Stock will be able to require us to redeem in cash any or all of the holder’s Series B Preferred Stock at a premium set forth in the Certificate of Designations.

We are subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisition and investment transactions, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.

The November Warrants are exercisable for Warrant Shares immediately at an exercise price of $7.75 per share (the “Exercise Price”) and expire five years from the date of issuance. The Exercise Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Exercise Price (subject to certain exceptions).

In connection with the November Purchase Agreement, we and the November Investors entered into a Registration Rights Agreement (the “November Registration Rights Agreement”) on November 17, 2022. Under the terms of the November Registration Rights Agreement, we agreed to register 200% of the Series B Preferred Shares, the Warrant Shares and the shares of Common stock issuable as amortization payments as well as any shares of Common stock paid as dividends. We filed a registration statement for the resale of such securities on December 16, 2022. We also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement.

In connection with the November Private Placement, pursuant to an Engagement Letter, between the Company and Katalyst Securities LLC (the “November Placement Agent”), the Company paid the November Placement Agent (i) a cash fee equal to 7% of the gross proceeds from any sale of securities in the November Private Placement and (ii) warrants to purchase shares of Common Stock equal to 3% of the number of shares of Common stock that the Series B Preferred Shares are initially convertible into, with an exercise price of $7.75 per share and a five-year term.

On June 1, 2023, the Company paid the holders of the Series B Preferred Stock approximately $1.64 million to satisfy the first amortization payment due. On June 30, 2023, the holders of the Series B Preferred Stock elected to defer the cash payment due on July 1, 2023 of approximately $1.14 million to August 1, 2023. On July 13, 2023, the holders of the Series B Preferred Stock elected to convert cash payments due on August 1, 2023 of approximately $2.16 million into 3,125,907 shares of Common Stock. On July 31, 2023, the holders of the Series B Preferred Stock elected to defer cash payments due on August 1, 2023 of approximately $953,000 to September 1, 2023. On August 1, 2023, the Company provided notice to the Series B Preferred Stock investors that it would issue 1,680,675 shares of pre-amortization Common Stock to satisfy the amortization payment due September 1, 2023. As of August 10, 2023, 2,799,249 total shares of Common Stock have been issued to the holders of the Series B Preferred Stock.

### Results of Most Recent Extended Confirmatory Phase 2 Clinical Trial

On July 23, 2020, we entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for our Phase 2 clinical study assessing the safety, tolerability and long-term efficacy of Bryostatin-1 in the treatment of moderately severe AD subjects not receiving memantine treatment. On January 22, 2022, the Company executed a change order with WCT to accelerate trial subject recruitment totaling approximately $1.4 million. The updated total estimated budget for the services, including pass-through costs, is approximately $11.0 million. As previously disclosed, on January 22, 2020, we were granted a $2.7 million award from the NIH, which award is being used to support the 2020 Study, resulting in a current estimated net budgeted cost of the 2020 Study to us of $8.3 million. Of the $2.7 million grant, virtually all has been received as of February 22, 2022.

As of June 30, 2023, we incurred cumulative expenses of approximately $10.5 million associated with services provided by WCT and certain pass-through expenses incurred by WCT, which was offset by NIH reimbursements recognized of $2.7 million and, for the three and six months ended June 30, 2023, we incurred expenses of approximately $77,000 and $400,000 associated with services provided by WCT and certain pass-through expenses incurred by WCT.

On December 16, 2022, we issued a press release announcing that an extended confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD (Study #204) did not achieve statistical significance on the primary endpoint, which was change from baseline to Week 13 in the SIB total score assessment obtained after completion of the second seven-dose course of treatment (week 28 of trial). On March 7, 2023, we announced results of our analysis of secondary endpoints and post hoc analysis from our Phase 2 study of Bryostatin-1. In the secondary endpoint analysis, changes from baseline at Weeks 9, 20, 24, 30, and 42 in the SIB (Severe Impairment Battery) total score were not statistically significant in the total patient population, and no pre-specified secondary endpoints were met with statistical significance in the low-to-moderately severe AD patient stratum. However, nearly all pre-specified secondary endpoints in the most advanced and severe AD (MMSE: 10-14) patient population, with baseline MMSE-2 (Mini-Mental State Examination, 2nd Edition) scores of 10-14, were achieved with statistical significance (p = \<0.05, 2-tailed). Data also showed statistical significance in exploratory secondary endpoints for the MMSE-2 10-14 stratum, and post hoc analysis was positive.

#### Open Label Dose Ranging Clinical Trial

On May 12, 2022, the Company entered into a services agreement with WCT (the “2022 Services Agreement”). The 2022 Services Agreement relates to services for a Phase 2 “open label,” dose ranging study, clinical trial assessing the safety, tolerability and efficacy of Bryostatin-1 administered via infusion in the treatment of moderately severe to severe AD subjects not receiving memantine treatment (the “2022 Study”).

Pursuant to the terms of the 2022 Services Agreement, WCT provided services to enroll approximately 12 2022 Study subjects. The first 2022 Study site was initiated during the third quarter of 2022. The total estimated budget for the services, including pass-through costs, is currently approximately $1.5 million. Either party may terminate the 2022 Services Agreement without cause upon 90 days prior written notice. Furthermore, in the event of a material breach by the other party, which breach is not cured by the breaching party, the other party may terminate the agreement upon 30 days’ prior written notice. The Company terminated the 2022 Services Agreement in December 2022.

The Company incurred approximately $1.6 million of cumulative expenses associated with the current 2022 Study as of June 30, 2023. Of the total $1.6 million incurred for the trial as of June 30, 2023, approximately $33,000 and $157,000 is reflected in the statement of operations, respectively and $0 for the comparable 2022 periods. As of June 30, 2023, $0 of WCT 2022 Study prepayments is included as a prepaid expense and other current assets in the Company’s balance sheet. In addition, approximately $55,000 is included in accounts payable and accrued expenses as of June 30, 2023.

### Other Development Projects

To the extent resources permit, we may pursue development of selected technology platforms with indications related to the treatment of various disorders, including neurodegenerative disorders such as AD, based on our currently licensed technology and/or technologies available from third party licensors or collaborators.

#### Nemours Agreement

On September 5, 2018, we announced a collaboration with Nemours, a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours A.I. DuPont Hospital (“Nemours”) to initiate a clinical trial using Bryostatin-1, under Orphan Drug Status, to treat Fragile X. We intend to provide the Bryostatin-1 drug product candidate and obtain the IND and Nemours intends to provide the clinical site and attendant support for the trial. We and Nemours, jointly, will develop the trial protocol. We currently estimate our total trial and IND cost to be approximately $2 million. As of June 30, 2023, we have incurred cumulative expenses associated with this agreement of approximately $100,000.

We have filed for an IND with the FDA. The FDA has placed the development of the IND on clinical hold pending completion of further analytics relating to drug pharmacokinetics and pharmacodynamics. We are currently evaluating its plans to advance Fragile X development.

#### Cleveland Clinic

On February 23, 2022, we announced our collaboration with the Cleveland Clinic to pursue possible treatments for Multiple Sclerosis, and on July 19, 2023, we announced that we had entered into an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in MS. Cleveland Clinic will manage the clinical trial’s implementation, including an IND submission to the FDA and patient enrollment. The total estimated costs associated with this collaboration are approximately $2.0 million.

### Results of Operations

### Comparison of the six months ended June 30, 2023 and 2022

The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022:

| ​ ​ ​ ​ Operating Expenses: | ​ ​ ​ ​ | ​ ​ Six Months ended June 30, 2023 | ​ ​ | ​ ​ 2022 | ​ ​ ​ ​ | ​ ​ ​ ​ Dollar Change | ​ ​ ​ | ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Research and development expenses | ​ | $1,184,928 | ​ | $3,427,175 | ​ | $(2,242,247) | ​ | (65.4)% |
| General and administrative expenses | ​ | $3,566,726 | ​ | $3,651,748 | ​ | $(85,022) | ​ | (2.3)% |
| Other income (loss), net | ​ | $(1,054,084) | ​ | $49,097 | ​ | $(1,103,181) | ​ | (2,246.9)% |
| Net loss | ​ | $5,805,738 | ​ | $7,029,826 | ​ | $(1,224,088) | ​ | (17.4)% |

### Operating Expenses

#### Overview

Total operating expenses for the six months ended June 30, 2023 were $4,751,654 as compared to $7,078,923 for the six months ended June 30, 2022, a decrease of approximately 32.9%. The decrease in total operating expenses is due to the decrease in research and development activities and general and administrative expenses.

#### Research and Development Expenses

For the six months ended June 30, 2023, we incurred $1,184,928 in research and development expenses as compared to $3,427,175 for the six months ended June 30, 2022, a decrease of approximately 65.4%. These expenses were incurred primarily pursuant to developing the potential AD therapeutic product, specifically expenses relating to our ongoing Phase 2 clinical trial for AD. Of these expenses, for the six months ended June 30, 2023, $842,756 was incurred principally relating to our current confirmatory clinical trial and our Phase 2 dose ranging study and related storage of drug product, $155,868 for clinical consulting services, $10,247 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $26,468 for development of alternative drug supply with Stanford University and $149,589 of non-cash stock options compensation expense; comparatively, for the six months ended June 30, 2022, $2,943,402 was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $152,658 for clinical consulting services, $14,931 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $23,481 for development of alternative drug supply with Stanford University and $292,703 of non-cash stock options compensation expense.

Our research and development expenses are leveling off as our current Phase 2 clinical trial for AD was materially concluded by the end of 2022 and our Phase 2 dose ranging study was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.

#### General and Administrative Expenses

We incurred $3,566,726 and $3,651,748 of general and administrative expenses for the six months ended June 30, 2023 and 2022, respectively, a decrease of approximately 2.3%. During the six months ended June 30, 2023, $648,092 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $601,507 for the six months ended June 30, 2022; $493,316 was incurred for legal expenses versus $207,019 for the 2022 comparable period. The increase in legal fees for 2023 is based upon the increased fees for special stockholder vote requirements and for regulatory compliance; $472,815 was incurred for outside operations consulting services during the six months ended June 30, 2023, versus $589,454 for the comparable period in 2022. The decrease for the 2023 period is based upon a decrease in non-cash compensation paid; $74,048 was incurred for travel expenses during the six months ended June 30, 2023, versus $39,131 for the comparable period in 2022 as post-COVID travel has increased; $240,628 was incurred for investor relations services during the six months ended June 30, 2023, versus $133,569 for the comparable period in 2022, with the increase for the current period based upon engaging additional consultants to assist with Company communications; $185,209 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the six months ended June 30, 2023, versus $109,725 for the comparable period in 2022. The increase for the current period is primary attributable to additional audit work for the November Private Placement and auditor change; $387,164 was incurred for insurance during the six months ended June 30, 2023, versus $365,544 for the comparable period in 2022; $235,846 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the six months ended June 30, 2023, versus $170,254 for the comparable period in 2022, with the increase for 2023 primary attributable to recognizing Delaware franchise tax quarterly; and $829,608 was recorded as non-cash stock options compensation expense during the six months ended June 30, 2023, versus $1,435,545 for the comparable period in 2022.

#### Other Income / Expense

We recognized a total other loss of $1,054,084 for the six months ended June 30, 2023 as compared to a total gain of $49,097 for the six months ended June 30, 2022, which consisted, for 2023, of interest income on funds deposited in interest bearing money market accounts and changes in fair value of warrant liability and derivative liability versus interest income only for 2022. The increase in interest income of $774,419 is primarily attributable to the increase in money market interest income rates and increase in cash balances. The total decrease is primarily attributable to the increase in fair value of derivative liability of $2,258,600 and the increase in fair value of warrant liability of $381,000 partially offset by the increase in interest income.

#### Net loss

We incurred losses of $5,805,738 and $7,029,826 for the six months ended June 30, 2023 and 2022, respectively. The decreased loss was primarily attributable to the decrease in net research and development expenses associated with our current Phase 2 confirmatory clinical trial and general and administrative expenses and other income.

### Comparison of the three months ended June 30, 2023 and 2022

The following table summarizes our results of operations for the three months ended June 30, 2023 and 2022:

| ​ ​ ​ ​ Operating Expenses: | ​ ​ ​ | ​ ​ Three Months ended June 30, 2023 ​ ​ | ​ | ​ ​ 2022 ​ ​ | ​ ​ ​ | ​ ​ ​ ​ Dollar Change ​ ​ | ​ ​ ​ ​ ​ ​ ​ % Change ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Research and development expenses | ​ | $307,211 | ​ | $1,941,101 | ​ | $(1,633,890) | (84.2)% |
| General and administrative expenses | ​ | $1,522,502 | ​ | $1,855,290 | ​ | $(332,788) | (17.9)% |
| Other income (loss), net | ​ | $(2,264,241) | ​ | $44,487 | ​ | $136,372 | 306.5% |
| Net loss | ​ | $4,093,954 | ​ | $3,751,904 | ​ | $342,050 | 9.1% |

### Operating Expenses

#### Overview

Total operating expenses for the three months ended June 30, 2023 were $1,829,713 as compared to $3,796,391 for the three months ended June 30, 2022, a decrease of approximately 51.8%. The decrease in total operating expenses is due to the decrease in research and development activities and general and administrative expenses.

#### Research and Development Expenses

For the three months ended June 30, 2023, we incurred $307,211 in research and development expenses as compared to $1,941,101 for the three months ended June 30, 2022, a decrease of approximately 84.2%. These expenses were incurred primarily in connection with developing the potential AD therapeutic product, specifically expenses relating to our ongoing Phase 2 clinical trial for AD. Of these expenses, for the three months ended June 30, 2023, $167,495 was incurred principally relating to our current confirmatory clinical trial and our Phase 2 dose ranging study and related storage of drug product, $74,121 for clinical consulting services, $4,986 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $10,746 for development of alternative drug supply with Stanford University and $49,863 of non-cash stock options compensation expense; comparatively, for the three months ended June 30, 2022, $1,680,918 was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $73,113 for clinical consulting services, $7,479 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $7,938 for development of alternative drug supply with Stanford University and $35,763 of non-cash stock options compensation expense.

Our research and development expenses have significantly decreased as our current Phase 2 clinical trial for AD was materially concluded by the end of 2022 and our Phase 2 dose ranging study was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.

#### General and Administrative Expenses

We incurred $1,522,502 and $1,855,290 of general and administrative expenses for the three months ended June 30, 2023 and 2022, respectively, a decrease of approximately 17.9%. During the three months ended June 30, 2023, $328,330 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $307,603 for the three months ended June 30, 2022; $211,635 was incurred for legal expenses versus $77,804 for the 2022 comparable period. The increase in legal fees for 2023 is based upon the prior year’s increased fees for special stockholder vote requirements and for regulatory compliance; $222,515 was incurred for outside operations consulting services during the three months ended June 30, 2023, versus $193,250 for the comparable period in 2022; $51,151 was incurred for travel expenses during the three months ended June 30, 2023, versus $24,479 for the comparable period in 2022 as post-COVID travel has increased; $55,967 was incurred for investor relations services during the three months ended June 30, 2023, versus $61,355 for the comparable period in 2022; $63,885 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the three months ended June 30, 2023, versus $87,677 for the comparable period in 2022; $193,441 was incurred for insurance during the three months ended June 30, 2023, versus $181,236 for the comparable period in 2022; $111,025 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the three months ended June 30, 2023, versus $76,849 for the comparable period in 2022; and $284,553 was recorded as non-cash stock options compensation expense during the three months ended June 30, 2023, versus $845,037 for the comparable period in 2022.

#### Other Income / Expense

We recognized a total other loss of $2,264,241 for the three months ended June 30, 2023 as compared to a total other gain of $44,487 for the three months ended June 30, 2022, which consisted, for 2023, of interest income on funds deposited in interest bearing money market accounts and changes in fair value of warrant liability and derivative liability versus interest income only for 2022. The increase in interest income of $382,672 is primarily attributable to the increase in money market interest income rates and increase in cash balances. The total decrease is primarily attributable to the increase in fair value of warrant liability of $207,000 and increase in fair value of derivative liability of $2,484,400 partially offset by the increase in interest income.

#### Net loss

We incurred losses of $4,093,954 and $3,751,904 for the three months ended June 30, 2023 and 2022, respectively. The increased loss was primarily attributable to the increase in other losses mostly offset by both the decreases in net research and development expenses associated with our current Phase 2 confirmatory clinical trial and general and administrative expenses.

### Financial Condition, Liquidity and Capital Resources

### Cash and Working Capital

Since inception, we have incurred negative cash flows from operations. As of June 30, 2023, we had working capital of $30,643,068 as compared to working capital of $37,272,851 as of December 31, 2022. The $6,629,783 decrease in working capital was primarily attributable to approximately $5.3 million of operating expenses, preferred stock dividends of approximately $0.7 million and sources of cash of approximately $2.0 million partially offset by non-cash expenses of approximately $0.6 million and interest income of approximately $0.8 million.

We expect that our current cash and cash equivalents of approximately $32.5 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q, which would include the continuing development of Bryostatin-1, our novel drug candidate targeting the activation of PKCε, our initiation and possible development of a therapeutic for MS and other possible therapeutics.

We expect to require additional capital in order to initiate, pursue and complete all potential AD clinical trials and obtain regulatory approval of one or more therapeutic candidates. However, additional future funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, and may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, would likely materially harm our business and financial condition.

### Sources and Uses of Liquidity

We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we continue to develop AD and other therapeutic products. We anticipate that this development may include clinical trials in addition to our current ongoing clinical trial and additional research and development expenditures.

| ​ ​ ​ | ​ ​ | ​ ​ Six Months Ended June 30, 2023 | ​ | ​ ​ 2022 |
| --- | --- | ---: | --- | --- |
| Cash used in operating activities | ​ | $2,935,299 | ​ | $6,009,489 |
| Cash used in investing activities | ​ | ​ 2,707 | ​ | ​ 3,029 |
| Cash used in (provided by) financing activities | ​ | 1,641,064 | ​ | ​ (553,150) |

### Net Cash Used in Operating Activities

Cash used in operating activities was $2,935,299 for the six months ended June 30, 2023, compared to $6,009,489 for the six months ended June 30, 2022. The $3,074,190 decrease primarily resulted from the decrease in net loss of approximately $1.2 million, the decrease in prepaid expenses of approximately $0.1 million and the increase in accounts payable and accrued expenses of approximately $0.7 million, and the changes in fair value of non-cash warrant and derivative liabilities totaling approximately $1.9 partially offset by an increase in non-cash stock-based compensation of approximately $0.8 million.

### Net Cash Used in Investing Activities

Net cash used in investing activities was $2,707 for the six months ended June 30, 2023 compared to $3,029 for the six months ended June 30, 2022. The cash used in investing activities for the six months ended June 30, 2023 was for capital expenditures.

### Net Cash Used in / Provided by Financing Activities

Net cash used in financing activities was $1,641,064 for the six months ended June 30, 2023 compared to cash provided by financing activities of $553,150 for the six months ended June 30, 2022. The net cash used in financing activities for the 2023 period was for paying dividends and redeeming part of the investment made by investors in the November Private Placement. Funds provided by financing activities for the comparable 2022 period resulted from the exercise of investor warrants issued in 2021.

## Controls and procedures

As filed, 3,392 characters.

### Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal financial and accounting officer, respectively, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are not effective due to: inadequate segregation of duties consistent with control objectives in the areas over certain payroll and banking systems and user access controls; ineffective processes over period end financial disclosure and reporting including documentation of GAAP disclosure and reporting reviews supporting the financial reporting process and changes to chart of accounts; and ineffective information technology (IT) general computing controls including lack of risk and design assessments supporting IT security policies and procedures, user access, and IT controls within third party contracts. These weaknesses may affect management’s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.

We previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, that our management, including our Chairman of the Board, principal executive officer and principal financial and accounting officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in the 2013 Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, such internal controls and procedures were not effective to detect the inappropriate application of US generally accepted accounting principles.

Based on management’s review, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were ineffective as of June 30, 2023. Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that financial statements, and other financial information included in this Quarterly Report on Form 10-Q, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this Quarterly Report on Form 10-Q.

### Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

### PART II

### OTHER INFORMATION

## Risk factors

As filed, 463 characters.

You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K. There have been no material changes from the risk factors disclosed in our 2022 Annual Report on Form 10-K. We may disclose changes to risk factors from time to time in our future filings with the SEC.

Filed Aug 14, 2023.
Source: SEC EDGAR, the filing index for accession 0001410578-23-001919. Last ingested by Listed: Nov 2, 2026, 06:08 ET. No prices; not investment advice.
